• Ensysce submitted a Phase 2a protocol for CY200 in complex regional pain syndrome type 1 to the UK MHRA for regulatory review.
• The randomized, double-blind, placebo-controlled study is planned to run in the UK, assessing efficacy, safety, tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609240800ACCESSWRNAPR_____1226508) on September 24, 2026, and is solely responsible for the information contained therein.